Mizoribine provides effective treatment of sequential histological change of arteritis and reduction of inflammatory cytokines and chemokines in an animal model of Kawasaki disease

BACKGROUND: Intravenous immunoglobulin (IVIg) treatment results in an effective response from patients with acute-phase Kawasaki disease (KD), but 16.5% of them remain nonresponsive to IVIg. To address this therapeutic challenge, we tried a new therapeutic drug, mizoribine (MZR), in a mouse model of...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Kei, Oharaseki, Toshiaki, Nagao, Tomokazu, Yokouchi, Yuki, Yamada, Hitomi, Nagi-Miura, Noriko, Ohno, Naohito, Saji, Tsutomu, Okazaki, Tomio, Suzuki, Kazuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3239324/
https://www.ncbi.nlm.nih.gov/pubmed/21958311
http://dx.doi.org/10.1186/1546-0096-9-30

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3239324/
https://www.ncbi.nlm.nih.gov/pubmed/21958311
http://dx.doi.org/10.1186/1546-0096-9-30

Ejemplares similares